Ataibeckley (ATAI) Stock
Mental health biotech developing multiple treatment options. Here's the price, business snapshot, and what's worth knowing about Ataibeckley in July 2026.
ATAI Life Sciences NV is a clinical-stage biotechnology company focused on developing new treatments for mental health disorders. The group follows a platform approach, backing and incubating subsidiaries that advance both psychedelic-assisted and non-psychedelic therapies across indications such as depression, post-traumatic stress disorder and substance-use disorders. ATAI’s business model aims to diversify scientific risk by supporting multiple programmes rather than a single asset, and its market capitalisation (about $1.41bn) reflects investor interest in the emerging mental‑health therapeutics space. Investing in ATAI means weighing the potential of transformative clinical results against the high volatility typical of biotech: many programmes are early stage, outcomes are binary, regulatory pathways are evolving, and the company may require further capital. This is general, educational information only and not personal advice; values can rise and fall and returns are not guaranteed. Consider suitability for your goals and risk tolerance before acting.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying ATAIBECKLEY's stock with a target price of $12.46, indicating significant growth potential.
Financial Health
ATAIBECKLEY INC is generating moderate revenue and cash flow, with a reasonable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ATAI
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: 17 June 2025
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: 15 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline diversity
ATAI funds multiple programmes across different mechanisms, which can spread scientific risk — though individual trials still carry binary outcomes and uncertainty.
Clinical catalysts ahead
Upcoming trial readouts and regulatory steps could materially affect the stock; these events offer potential opportunity but also volatility.
Market and regulation
Growing interest in mental-health therapeutics supports investor attention, yet regulatory change and funding needs remain key risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.